HIMA (US Health Industry Manufacturers Association) lobbies FDA again over latex regulations
This article was originally published in Clinica
The US Health Industry Manufacturers Association (HIMA) has made another attempt to persuade the FDA to lessen the burden of its latex rubber regulations on manufacturers of in vitro diagnostics.
You may also be interested in...
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.
UK-based charity International Health Partners has launched a fresh appeal to double the value funds being raised to send essential medicines to expectant mothers and children at risk of death in areas of extreme deprivation.